What Does the M Checkpoint Check During Mitosis?

The M checkpoint, more precisely called the spindle assembly checkpoint (SAC), verifies that every single chromosome is correctly attached to the spindle apparatus before the cell is allowed to pull its chromosomes apart and divide. It is, in essence, a quality-control system that prevents a cell from splitting its genetic material unevenly. Even one unattached chromosome is enough to hold everything in place, and the checkpoint will keep the cell paused in mitosis until the problem is fixed or the cell is directed to die.

What the Checkpoint Actually Detects

During mitosis, each duplicated chromosome must connect to protein cables called spindle microtubules through a structure on the chromosome called the kinetochore. The checkpoint monitors these kinetochore-microtubule connections. The clearest signal that activates it is an unattached kinetochore, one that has not yet grabbed onto any microtubule at all. Unattached kinetochores act as biochemical platforms that generate a “wait” signal, catalyzing the formation of a protein complex that blocks the cell from moving forward.¹

There has been a long-running debate about whether the checkpoint also senses tension. When a chromosome is attached correctly, its two sister chromatids are pulled toward opposite poles of the cell, and that tug-of-war creates mechanical tension at the kinetochore. When a chromosome is attached incorrectly, say both sister chromatids are being pulled to the same pole, there is little or no tension. Some experiments have pointed to lack of attachment as the key signal, while others suggest absence of tension matters too; distinguishing the two has been difficult because tension and proper attachment are deeply intertwined.²

More recent work has started to disentangle these signals. One study showed that low tension on chromosomes that are attached to both poles can delay the onset of chromosome separation independently of detachment. That delay is shorter than the one caused by a completely unattached kinetochore, and it relies on different checkpoint proteins (Bub1 and Bub3 rather than Mad1 and Mad2).³ So the emerging picture is that the checkpoint reads at least two inputs: “Is there an attachment?” and “Does that attachment feel right?” The first is the louder alarm; the second is a quieter warning that buys the cell a bit more time.

How a Single Unattached Chromosome Stalls the Whole Cell

The checkpoint’s power comes from its ability to amplify a tiny local signal into a cell-wide block on division. Here is how that works in plain terms. An unattached kinetochore serves as a sort of assembly station. A key enzyme called Mps1 kinase localizes to unattached kinetochores and kickstarts the signaling cascade.⁴ Mps1 helps recruit and activate other checkpoint proteins, including Mad1 and Mad2, which sit on that kinetochore and convert free-floating Mad2 in the surrounding cell fluid into a form that can lock onto a protein called Cdc20.

This is where the amplification happens. At the kinetochore, one Mad2 molecule can help produce multiple copies of an inhibitory complex, creating a catalytic chain reaction rather than a one-for-one exchange.⁵ The end product is the mitotic checkpoint complex, or MCC, assembled from four proteins: BubR1, Bub3, Cdc20, and Mad2.⁶ Unattached kinetochores churn out MCC at a rate that floods the cell, which is why even a single unattached chromosome can keep the entire cell in arrest.

What the MCC Actually Blocks

The target of all this signaling is a large molecular machine called the anaphase-promoting complex, or APC/C. Think of the APC/C as the cell’s “go” switch for division: when active, it tags certain proteins for destruction, and that destruction triggers chromosome separation and exit from mitosis.⁷ The MCC blocks the APC/C in a remarkably thorough way. It physically binds to Cdc20 (the APC/C’s main activating partner), plugging the sites where the APC/C would normally recognize its target proteins for degradation.⁸ Structural studies have shown that the MCC also blocks access by the enzyme that would attach destruction tags, creating a double lock.⁹

Among the APC/C’s most important targets are securin and cyclin B. Securin acts like a leash on the enzyme that would cut the protein glue holding sister chromatids together. Cyclin B keeps the cell in a mitotic state. As long as the MCC keeps the APC/C gagged, securin and cyclin B remain intact, sister chromatids stay glued, and the cell sits in mitosis. The checkpoint is not just delaying a process; it is physically preventing the molecular events that would pull the chromosomes apart.

The Role of Tension Sensing

Attachment alone is not always enough to guarantee accuracy. A chromosome can be attached to spindle microtubules and still be attached incorrectly, for instance when both kinetochores connect to the same pole rather than to opposite poles. This is where tension sensing becomes critical. Proper biorientation, where each kinetochore is pulled toward the opposite pole, generates tension across the centromere region holding the sister chromatids together. A kinase called Aurora B sits at the centromere and functions as the tension sensor. When tension is low, Aurora B destabilizes the faulty microtubule attachments, effectively detaching the chromosome so it can try again.¹⁰

This error-correction mechanism feeds back into the checkpoint itself. When Aurora B strips away a faulty attachment, the kinetochore becomes unattached again, and the checkpoint reactivates through the standard Mad1/Mad2 pathway. Tension sensing and attachment sensing are therefore not entirely independent systems. They form an integrated loop: Aurora B corrects bad attachments, and the checkpoint holds the cell in arrest until those corrections are made. The cell does not proceed until every chromosome is both attached and under proper tension.

How the Checkpoint Switches Off

Once every kinetochore in the cell has achieved stable, tension-bearing attachment to spindle microtubules, the checkpoint must shut down rapidly. And it does. The transition from full arrest to chromosome separation is remarkably fast and synchronized, occurring within minutes of the last chromosome achieving proper biorientation.¹¹

Silencing involves several parallel events. Checkpoint proteins like Mad1 and Mad2 are stripped from kinetochores once stable attachment is established, so the assembly station that was churning out MCC simply shuts down. Existing MCC in the cell is disassembled and Cdc20 is freed up to activate the APC/C. The speed of this silencing matters: if it were slow or sloppy, some chromosomes might start separating before others, creating the same kind of errors the checkpoint exists to prevent.

When the Checkpoint Fails

A weakened checkpoint allows cells to divide before all chromosomes are properly attached. The result is aneuploidy, where daughter cells end up with the wrong number of chromosomes. In mice, partially reducing the levels of checkpoint genes like Mad1, Mad2, Bub1, BubR1, or Bub3 leads to premature separation of sister chromatids and chromosome missegregation, driving a form of genetic instability that is a hallmark of many cancers.¹² The relationship between the checkpoint and cancer is not straightforward, though. Complete loss of checkpoint function is usually lethal to cells. It is the partial weakening, enough to let occasional errors through but not enough to kill the cell outright, that fuels tumor evolution.

There is also a phenomenon called mitotic slippage. A cell can be held in mitotic arrest by the checkpoint, but if it stays arrested long enough, cyclin B gradually leaks away through low-level degradation that bypasses the checkpoint’s block on the APC/C. Once cyclin B drops below a critical threshold, the cell exits mitosis without ever dividing, ending up as a single cell with double the normal DNA content.¹³ Mitotic slippage is a significant concern in cancer treatment because many chemotherapy drugs, including paclitaxel, work partly by activating the checkpoint and trapping cancer cells in mitosis. If those cells slip out of arrest instead of dying, they survive and can keep growing.¹⁴

Cancer Drugs That Exploit the Checkpoint

Understanding the checkpoint has opened up two very different therapeutic strategies. The older and better-known approach uses drugs like paclitaxel (Taxol) that stabilize microtubules, preventing the spindle from assembling properly. This keeps kinetochores unattached or poorly attached, which activates the checkpoint and traps dividing cancer cells in mitosis. In practice, though, the drug concentrations that actually reach tumors may be lower than what is needed for a clean mitotic arrest; at those lower doses, cells can end up undergoing abnormal divisions with multiple spindle poles rather than simply stalling.¹⁵

The newer approach goes in the opposite direction: instead of activating the checkpoint, it disables it. Drugs targeting Mps1, the kinase that initiates checkpoint signaling at kinetochores, are being developed to force cancer cells through mitosis so quickly that they cannot fix attachment errors. The idea is that cancer cells, which often already have unstable chromosomes, will accumulate lethal levels of aneuploidy if you strip away the checkpoint entirely. Mps1 is overexpressed in many tumor types, where it can reduce checkpoint sensitivity enough to let aneuploid cells survive. Blocking it pushes those cells over the edge.¹⁶ Two clinical candidates targeting Mps1 have reached human trials, though none has yet received approval.¹⁷

The challenge with both strategies is the same: healthy dividing cells also rely on the checkpoint. Bone marrow cells, gut lining cells, and other rapidly dividing tissues are vulnerable to drugs that mess with mitosis, which is why chemotherapy side effects tend to concentrate in those tissues. The therapeutic window between killing cancer cells and harming normal ones remains narrow.

The Checkpoint Is Weaker in Egg Cells

One of the more surprising findings in this field is that the spindle assembly checkpoint does not work with the same stringency in all cell types. In standard body cells, even a single misaligned chromosome is enough to halt division. In mammalian egg cells (oocytes) undergoing meiosis I, the checkpoint appears to tolerate one or even a few misaligned chromosomes without stopping the process.¹⁸

This has real consequences. Chromosome errors during egg cell division are the primary cause of conditions like Down syndrome, and the frequency of these errors rises sharply with maternal age. The relative permissiveness of the meiotic checkpoint in oocytes compared to the tight surveillance in body cells is one of the reasons why egg cells are more error-prone. Researchers are still working out why the checkpoint evolved to be less strict in oocytes. One possibility is that the very large size of the egg cell dilutes the checkpoint signal. Studies in early embryos of other organisms have shown that checkpoint strength depends on the ratio of kinetochores to the volume of the surrounding cell fluid; a bigger cell means each unattached kinetochore generates a proportionally weaker signal relative to the cytoplasm.¹⁹

Cell Size and Checkpoint Strength

The idea that checkpoint strength is not fixed but scales with cell geometry is a relatively recent insight. Work in worm embryos demonstrated that the kinetochore-to-cytoplasm ratio determines how strongly the checkpoint can hold a cell in arrest. Adding extra centromeres (the chromosome regions that build kinetochores) strengthened the checkpoint, while simply adding more DNA without functional centromeres did not.²⁰

This finding helps explain large variations in checkpoint behavior across different cell types and organisms. Very early embryonic cells, which are large and divide rapidly, tend to have weak or absent checkpoint responses. As development proceeds and cells get smaller through successive divisions, the checkpoint becomes more robust. Some cancer cells are abnormally large, and this framework predicts that their checkpoints may be inherently weaker, an intriguing angle for understanding why tumor cells tolerate so much chromosome instability.

How the Checkpoint Was Discovered

The genes behind the checkpoint were found through a beautifully simple genetic strategy in budding yeast during the early 1990s. Researchers looked for yeast mutants that failed to arrest when their spindles were disrupted by drugs. The mutants they found fell into two groups: the MAD genes (mitotic arrest deficient) and the BUB genes (budding uninhibited by benzimidazole).¹⁹ When spindle assembly was disrupted in these mutants, the cells barreled through division anyway and quickly lost viability.²¹ The striking conservation of these genes from yeast to humans underscores how fundamental the checkpoint is. The same core proteins, Mad1, Mad2, BubR1, Bub1, and Bub3, do essentially the same job in human cells as they do in single-celled yeast, despite over a billion years of evolutionary separation.²²

Lipid Metabolism and Checkpoint Drug Resistance

One of the more unexpected recent findings connects the checkpoint to lipid metabolism. Researchers found that a protein involved in lipid transport, OSBPL11, influences how cells respond to checkpoint-activating cancer drugs. When OSBPL11 was depleted in cells treated with spindle poisons like paclitaxel, cyclin B levels dropped faster and mitotic slippage accelerated, meaning the cells escaped from drug-induced arrest more quickly and were more likely to survive.²³ The effect depended on OSBPL11’s ability to bind and transport lipids; mutant versions that could not handle lipids failed to rescue the slippage phenotype. Blocking APC/C activity with a separate inhibitor reversed the accelerated slippage, confirming that the connection runs through the same cyclin B degradation pathway that the checkpoint normally controls.

This matters because it suggests the checkpoint’s effectiveness is influenced by cellular processes that seem far removed from chromosome biology. If lipid metabolism can tip the balance between checkpoint-mediated cell death and mitotic slippage, tumor cells with altered lipid handling might be inherently more resistant to drugs like paclitaxel. It is the kind of finding that could eventually help clinicians predict which patients will respond to spindle-targeting chemotherapies and which will not.